Life Sciences Tools and Services
Company Overview of BioNano Genomics, Inc.
BioNano Genomics, Inc. operates as a genome mapping company. The company develops Irys, a flexible platform capable of providing single-molecule analysis of extremely long DNA. Its platform provides researchers and clinicians an organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. The company’s Irys system includes IrysPrep reagent kits that supplement readily available enzymes with other enzymes, dyes, and buffers needed to label non-amplified DNA for the Irys system; IrysChips for sample handling of precious or minute samples in a convenient 2-flowcell format; Irys Instrum...
9640 Towne Centre Drive
San Diego, CA 92121
Founded in 2003
Key Executives for BioNano Genomics, Inc.
Chief Executive Officer, President and Director
Founder and Chief Scientific Officer
Vice President of Finance
Vice President of Corporate Development
Compensation as of Fiscal Year 2016.
BioNano Genomics, Inc. Key Developments
BioNano Genomics, Inc. Announces Executive Changes
Sep 8 16
BioNano Genomics announced that it has elected David Barker, Ph.D., former Chief Scientific Officer of Illumina, as Chairman of the Board. BioNano has further strengthened its executive management team with two additional appointments: Sean Paolino to Vice President, Finance and Warren Robinson to Vice President, Global Sales and Marketing.
BioNano Genomics and Berry Genomics Co., Ltd. to Co-Develop Next-Generation Mapping System for Chinese Food and Drug Administration-Approved Clinical Use in China
Aug 17 16
Berry Genomics Co., Ltd. announced that it has chosen BioNano Genomics' Irys system for next-generation mapping (NGM) as the platform on which Berry will seek Chinese Food and Drug Administration (CFDA) regulatory approval for a number of clinical indications in China. Under the agreement, the companies will co-develop an NGM system to provide cost-effective, easy-to-use assays for detection of chromosomal structural variations. The new assays and instrument system are to be validated in clinical settings in China and submitted for review under the CFDA's medical device registration process. The system will integrate proprietary assays designed by BioNano and Berry with a next-generation mapping instrument based on BioNano's Irys platform. Berry will exclusively manufacture and market the system and assays in China for clinical use in selected indications. BioNano will continue to market its Irys system in China to the rest of the research community, including genomics centers, governmental and academic institutions, translational research facilities and pharmaceutical companies.
BioNano Genomics, Inc. Presents at UBS Genomics 2.0 Summit, Aug-10-2016 06:15 PM
Aug 7 16
BioNano Genomics, Inc. Presents at UBS Genomics 2.0 Summit, Aug-10-2016 06:15 PM. Venue: St. Regis Deer Valley, Park City, Utah, United States. Speakers: R. Erik Holmlin, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|